Novel minor histocompatibility antigens and uses thereof

Abstract

Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.

What is claimed is: 
     
         1 . A method of treating cancer, said method comprising administering to a male subject expressing a major histocompatibility complex (MHC) class I molecules of the HLA-B*44:03 allele in need thereof an effective amount of CD8 +  T lymphocytes recognizing an MHC class I molecule of the HLA-B*44:03 allele loaded with a minor histocompatibility antigen (MiHA) peptide of 9 to 14 amino acids comprising the sequence NESNTQKTY (SEQ ID NO: 36). 
     
     
         2 . The method of  claim 1 , wherein said subject in need thereof is an allogeneic stem cell transplantation (ASCT) recipient. 
     
     
         3 . The method of  claim 1 , wherein said cancer is a hematologic cancer. 
     
     
         4 . The method of  claim 3 , wherein said hematologic cancer is leukemia. 
     
     
         5 . The method of  claim 1 , wherein said CD8 +  T lymphocytes are ex vivo expanded primary CD8 +  T lymphocytes or CD8 +  T lymphocyte clones expressing a recombinant T cell receptor (TCR). 
     
     
         6 . The method of  claim 1 , wherein said method further comprises administering an effective amount of the MiHA peptide recognized by said CD8 +  T lymphocytes, and/or (ii) an antigen-presenting cell (APC) expressing at its surface MHC class I molecules comprising the MiHA peptide in their peptide binding groove. 
     
     
         7 . The method of  claim 1 , wherein said method further comprises culturing and expanding said CD8 +  T lymphocytes in the presence of cells expressing said MHC class I molecule loaded with said MiHA peptide in vitro prior to administration to the male subject, and wherein said CD8 +  T lymphocytes are from a female subject. 
     
     
         8 . The method of  claim 7 , wherein said male subject is an allogeneic stem cell transplantation (ASCT) recipient. 
     
     
         9 . The method of  claim 7 , wherein said cancer is a hematologic cancer. 
     
     
         10 . The method of  claim 9 , wherein said hematologic cancer is leukemia. 
     
     
         11 . The method of  claim 7 , wherein said method further comprises administering an effective amount of the MiHA peptide, and/or (ii) an antigen-presenting cell (APC) expressing at its surface MHC class I molecules comprising the MiHA peptide in their peptide binding groove. 
     
     
         12 . The method of  claim 1 , wherein said MiHA peptide consists of the sequence NESNTQKTY (SEQ ID NO: 36). 
     
     
         13 . The method of  claim 12 , wherein said male subject is an allogeneic stem cell transplantation (ASCT) recipient. 
     
     
         14 . The method of  claim 12 , wherein said cancer is a hematologic cancer. 
     
     
         15 . The method of  claim 14 , wherein said hematologic cancer is leukemia. 
     
     
         16 . The method of  claim 12 , wherein said CD8 +  T lymphocytes are ex vivo expanded primary CD8 +  T lymphocytes or CD8 +  T lymphocyte clones expressing a recombinant T cell receptor (TCR). 
     
     
         17 . The method of  claim 12 , wherein said method further comprises administering an effective amount of the MiHA peptide recognized by said CD8 +  T lymphocytes, and/or (ii) an antigen-presenting cell (APC) expressing at its surface MHC class I molecules comprising the MiHA peptide in their peptide binding groove. 
     
     
         18 . The method of  claim 12 , wherein said method further comprises culturing and expanding said CD8 +  T lymphocytes in the presence of cells expressing said MHC class I molecule loaded with said MiHA peptide in vitro prior to administration to the subject, and wherein said CD8 +  T lymphocytes are from a second subject that does not express said MiHA peptide.